Research Articles from literature

  1. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
  2. Screening of specific binding peptide targeting blood vessel of human esophageal cancer in vivo in mice.
  3. Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery.
  4. Novel Tetrapeptide, RGDF, Mediated Tumor Specific Liposomal Doxorubicin (DOX) Preparations.
  5. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.
  6. Efficient in vivo selection of a novel tumor-associated peptide from a phage display library.
  7. Isolation of peptide ligands that interact specifically with human glioma cells.
  8. A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery.
  9. Structure and activity of CPNGRC: a modified CD13/APN peptidic homing motif.
  10. Apoptosis imaging: beyond annexin V.
  11. Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides.
  12. Peptide arrays for screening cancer specific peptides.
  13. Targeting of hepatoma cell and suppression of tumor growth by a novel 12mer peptide fused to superantigen TSST-1.
  14. Isolation of cell specific peptide ligands using fluorescent bacterial display libraries.
  15. Selection of tumor-binding ligands in cancer patients with phage display libraries.
  16. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds.
  17. Phage display selection of peptides that inhibit metastasis ability of gastric cancer cells with high liver-metastatic potential.
  18. Lymphatic zip codes in premalignant lesions and tumors.
  19. Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide.
  20. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer.
  21. Characterization of a specific phage-displayed Peptide binding to vasculature of human gastric cancer.
  22. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase.
  23. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin.
  24. Effect of His-Gly-Lys motif derived from domain 5 of high molecular weight kininogen on suppression of cancer metastasis both in vitro and in vivo.
  25. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis.
  26. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma.
  27. Tumor vasculature address book: identification of stage-specific tumor vessel zip codes by phage display.
  28. Isolation of a colon tumor specific binding peptide using phage display selection.
  29. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
  30. Identification of peptide substrates for human MMP-11 (stromelysin-3) using phage display.
  31. Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells.
  32. Targeting the prostate for destruction through a vascular address.
  33. Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature.
  34. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
  35. Anti-neovascular therapy using novel peptides homing to angiogenic vessels.
  36. Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor.
  37. Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage.
  38. Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif.
  39. RGD-Tachyplesin inhibits tumor growth.
  40. Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells.
  41. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display.
  42. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.
  43. Identification of patient-specific peptides for detection of M-proteins and myeloma cells.
  44. NG2 proteoglycan-binding peptides target tumor neovasculature.
  45. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.
  46. Characterization of peptides that bind the tumor-associated Thomsen-Friedenreich antigen selected from bacteriophage display libraries.
  47. A role of chondroitin sulfate glycosaminoglycan binding site in alpha4beta1 integrin-mediated melanoma cell adhesion.
  48. Involvement of integrin alphavbeta3 in cell adhesion, motility, and liver metastasis of murine RAW117 large cell lymphoma.
  49. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors.
  50. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells.
  51. Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo.
  52. Targeting of albumin-embedded paclitaxel nanoparticles to tumors.
  53. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.
  54. The use of RGDGWK-lipopeptide to selectively deliver genes to mouse tumor vasculature and its complexation with p53 to inhibit tumor growth.
  55. Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer.
  56. Tissue-penetrating delivery of compounds and nanoparticles into tumors.
  57. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting.
  58. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer.
  59. A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy.
  60. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery.
  61. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
  62. Identification of binding peptides of the ADAM15 disintegrin domain using phage display.
  63. Radiolabeling and biodistribution of a nasopharyngeal carcinoma-targeting peptide identified by in vivo phage display.
  64. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer.
  65. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.
  66. Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas.
  67. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery.
  68. Identification of a novel peptide ligand of human vascular endothelia growth factor receptor 3 for targeted tumour diagnosis and therapy.
  69. Screening and identification of a targeting peptide to hepatocarcinoma from a phage display peptide library.
  70. Inhibitory effects of a specific phage-displayed peptide on high peritoneal metastasis of gastric cancer.
  71. Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands.
  72. Identification of one vasculature specific phage-displayed peptide in human colon cancer.
  73. Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of alphaVbeta3-expressing endothelial cells.
  74. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy.
  75. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity.
  76. Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma.
  77. Identification using phage display of peptides promoting targeting and internalization into HPV-transformed cell lines.
  78. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion.
  79. Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms.
  80. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.
  81. Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection.
  82. Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection.
  83. Preclinical evaluation of the breast cancer cell-binding peptide, p160.
  84. Nanoparticles for the optical imaging of tumor E-selectin.
  85. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries.
  86. TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
  87. Alpha v integrins as receptors for tumor targeting by circulating ligands.
  88. MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.
  89. Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment.
  90. Silk-based nanocomplexes with tumor-homing peptides for tumor-specific gene delivery.
  91. TMTP1, a novel tumor-homing peptide, specifically targets hematological malignancies and their metastases.
  92. Peptide PHSCNK as an integrin α(5)β(1) antagonist targets stealth liposomes to integrin-overexpressing melanoma.
  93. Molecular imaging of breast tumors using a near-infrared fluorescently labeled clusterin binding peptide.
  94. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide.
  95. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
  96. The effect of hydrophilic chain length and iRGD on drug delivery from poly(ε-caprolactone)-poly(N-vinylpyrrolidone) nanoparticles.
  97. A new phage-display tumor-homing Peptide fused to antiangiogenic Peptide generates a novel bioactive molecule with antimelanoma activity.
  98. Spider silk-based gene carriers for tumor cell-specific delivery.
  99. Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand.
  100. αvβ3-Integrin-targeting lanthanide complex: synthesis and evaluation as a tumor-homing luminescent probe.